Maxim Group Initiates Coverage On BioHarvest Sciences with Buy Rating, Announces Price Target of $12
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Source: Benzinga
Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.
Analyst Views on BHST
Wall Street analysts forecast BHST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHST is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.610
Low
12.00
Averages
13.00
High
14.00
Current: 5.610
Low
12.00
Averages
13.00
High
14.00
No data
About BHST
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
